Clinical Trial Update: Comparing the Effectiveness of IV Bezlotoxumab Versus Placebo in Decreasing Morbidity and Mortality in Patients With Fulminant C. Diff Requiring Surgery. [Phase 4]

View source ↗

Summary

Phase 4 trial comparing IV bezlotoxumab to placebo in fulminant Clostridioides difficile colitis patients requiring surgery; study status terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Clostridioides Difficile Colitis
• Sepsis

Drugs mentioned

• Bezlotoxumab (bezlotoxumab)

Snippet

Sponsor: Michael E Villarreal, MD | Conditions: Clostridia Difficile Colitis, Clostridium; Sepsis | Phase 4 | Status: TERMINATED